The study involves adults with metastatic colorectal cancer, a type of cancer that began in the colon or rectum and has spread to other parts of the body. One treatment being tested is an experimental drug called Precemtabart Tocentecan, which is given through an infusion (a slow drip into a vein). Another drug used in the study is bevacizumab, a medication that blocks the growth of new blood vessels that tumors need to grow. The standard comparison treatment combines two chemotherapy agents, trifluridine and tipiracil, taken as pills together with bevacizumab.
The purpose of the study is to determine whether the experimental drug, alone or together with the blood‑vessel‑blocking drug, can improve overall survival compared with the standard pill combination plus the blood‑vessel‑blocking drug.
Participants are randomly placed into one of three groups: one group receives the experimental drug alone, a second group receives the experimental drug combined with the blood‑vessel‑blocking drug, and a third group receives the standard pill combination together with the blood‑vessel‑blocking drug. Treatments are given in repeated cycles, and participants have regular clinic visits for check‑ups, blood tests, imaging scans, and monitoring for side effects. The study continues until the disease progresses or the treatment can no longer be tolerated.
Austria 
Belgium 
Denmark 
France 
Germany 
Italy 
Poland 
Spain 
The Netherlands